STOK · Categories · Form 4
STOK - SEC Form 4 insider transactions
Stoke Therapeutics Inc. (STOK) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for STOK
- SEC Form 4 filed by Kahn Clare4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Ticho Barry4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Allan Jonathan4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Ticho Barry4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Leggett Thomas4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Hoitt Jason4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Allan Jonathan4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Chief Patient Officer Hoitt Jason converted options into 10,000 shares, increasing direct ownership by 251% to 13,988 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Chief Financial Officer Leggett Thomas converted options into 14,750 shares (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 33,850 shares, increasing direct ownership by 171% to 53,648 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md converted options into 61,750 shares, increasing direct ownership by 126% to 110,874 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 25,475 shares, increasing direct ownership by 208% to 37,731 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Levin Arthur A sold $22,264 worth of shares (605 units at $36.80), decreasing direct ownership by 12% to 4,237 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Interim Executive Chair Tzianabos Arthur exercised 3,955 shares at a strike of $8.33 and sold $174,214 worth of shares (4,355 units at $40.00), decreasing direct ownership by 1% to 31,339 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Krainer Adrian R. sold $1,320,964 worth of shares (33,243 units at $39.74), decreasing direct ownership by 11% to 283,302 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Krainer Adrian R. sold $286,715 worth of shares (7,229 units at $39.66), decreasing direct ownership by 2% to 316,545 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by CHIEF MEDICAL OFFICER Ticho Barry4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Smith Ian F4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Leggett Thomas4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Patient Officer Hoitt Jason4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by GENERAL COUNSEL & CORP SEC Allan Jonathan4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Levin Arthur A converted options into 1,211 shares, increasing direct ownership by 33% to 4,842 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $128,411 worth of shares (3,978 units at $32.28), decreasing direct ownership by 25% to 11,831 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $433,385 worth of shares (13,430 units at $32.27), decreasing direct ownership by 21% to 49,124 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 10,000 shares and sold $167,115 worth of shares (5,358 units at $31.19), increasing direct ownership by 31% to 19,798 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md converted options into 26,250 shares and sold $466,959 worth of shares (15,001 units at $31.13), increasing direct ownership by 22% to 62,554 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 6,000 shares and sold $306,322 worth of shares (9,803 units at $31.25), decreasing direct ownership by 19% to 15,809 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 11,981 shares and sold $121,468 worth of shares (4,020 units at $30.22), increasing direct ownership by 111% to 15,156 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $64,541 worth of shares (2,136 units at $30.22) and converted options into 4,317 shares, increasing direct ownership by 4% to 51,305 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $138,268 worth of shares (4,576 units at $30.22) and converted options into 12,357 shares, increasing direct ownership by 66% to 19,612 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Krainer Adrian R. sold $1,202,719 worth of shares (40,472 units at $29.72), decreasing direct ownership by 11% to 323,774 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Krainer Adrian R. sold $1,092,058 worth of shares (40,472 units at $26.98), decreasing direct ownership by 10% to 364,246 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $152,566 worth of shares (5,931 units at $25.72), decreasing direct ownership by 45% to 7,195 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Smith Ian F4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $750,000 worth of shares (25,000 units at $30.00) and exercised 25,000 shares at a strike of $0.60 (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $1,065,206 worth of shares (42,461 units at $25.09), decreasing direct ownership by 46% to 49,124 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan exercised 10,000 shares at a strike of $9.15 and sold $250,650 worth of shares (10,000 units at $25.07) (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $126,316 worth of shares (5,343 units at $23.64), decreasing direct ownership by 29% to 13,126 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Levin Arthur A converted options into 1,211 shares, increasing direct ownership by 50% to 3,631 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Kaye Edward M. Md4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $109,325 worth of shares (5,501 units at $19.87), decreasing direct ownership by 23% to 18,469 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $1,245,698 worth of shares (61,885 units at $20.13), decreasing direct ownership by 40% to 91,585 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan exercised 10,000 shares at a strike of $7.07 and sold $444,809 worth of shares (22,117 units at $20.11), decreasing direct ownership by 51% to 11,831 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $51,158 worth of shares (2,805 units at $18.24), decreasing direct ownership by 10% to 23,970 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md sold $221,154 worth of shares (12,126 units at $18.24), decreasing direct ownership by 7% to 153,470 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $30,695 worth of shares (1,683 units at $18.24), decreasing direct ownership by 7% to 23,948 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 10,000 shares, increasing direct ownership by 60% to 26,775 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 6,000 shares, increasing direct ownership by 31% to 25,631 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Kaye Edward M. Md converted options into 26,250 shares, increasing direct ownership by 19% to 165,596 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $205,680 worth of shares (13,712 units at $15.00), decreasing direct ownership by 41% to 19,631 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $57,724 worth of shares (4,504 units at $12.82), decreasing direct ownership by 21% to 16,775 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- CHIEF MEDICAL OFFICER Ticho Barry sold $52,379 worth of shares (4,503 units at $11.63), decreasing direct ownership by 17% to 21,279 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Director Levin Arthur A converted options into 1,210 shares, increasing direct ownership by 100% to 2,420 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- Large owner Skorpios Trust sold $30,600,000 worth of shares (3,000,000 units at $10.20) (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Smith Julie4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Levin Arthur A4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Menzel Garry E4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Krainer Adrian R.4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Harrison Seth Loring4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SEC Form 4 filed by Director Burstein Jennifer4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)